Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 3 February 2026, 13:30 (CET) to 4 February 2026, 16:00 (CET)

PSUSA/00002709/202504

Human medicines European public assessment report (EPAR): Ztalmy, ganaxolone, Date of authorisation: 26/07/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Epidyolex, cannabidiol, Date of authorisation: 19/09/2019, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Jeraygo, aprocitentan, Revision: 3, Status: Authorised

Meeting of the HMA-EMA group focused on AI with industry stakeholders - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 February 2026, 10:00 (CET) to 4 February 2026, 11:30 (CET)

Human medicines European public assessment report (EPAR): Zyprexa, olanzapine, Date of authorisation: 27/09/1996, Revision: 47, Status: Authorised

Quality Innovation Group (QIG): Listen and learn focus group meeting on sustainability, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 March 2026 to 5 March 2026

Human medicines European public assessment report (EPAR): Aumseqa, Aumolertinib, Date of authorisation: 12/02/2026, Status: Authorised

EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026, 13:00 (CEST) to 2 July 2026, 16:00 (CEST)